Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease

Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease

Models of Huntington disease (HD) recapitulate some neuropathological features of the disease. However, a global natural history of neuroanatomy in a mouse expressing full-length huntingtin has not been conducted. We investigated neuropathological changes in the YAC128 murine model of HD using magne...

Full description

Bibliographic Details
Main Authors:	Jeffrey B. Carroll, Jason P. Lerch, Sonia Franciosi, Amanda Spreeuw, Nagat Bissada, R. Mark Henkelman, Michael R. Hayden
Format:	Article
Language:	English
Published:	Elsevier 2011-07-01
Series:	Neurobiology of Disease
Subjects:	Magnetic resonance imaging Huntington's Disease Mouse models Neuropathology
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996111001008

Similar Items

Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models
by: Rona K. Graham, et al.
Published: (2006-02-01)

Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease
by: Bissada Nagat, et al.
Published: (2011-08-01)

NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease
by: Mahmoud A. Pouladi, et al.
Published: (2012-12-01)

Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain
by: Jeremy M. Van Raamsdonk, et al.
Published: (2007-04-01)

Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease
by: Sonia Franciosi, et al.
Published: (2012-01-01)

Synaptic modulation of glutamate in striatum of the YAC128 mouse model of Huntington disease
by: Judy Cheng, et al.
Published: (2025-02-01)

Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease
by: Jessica M. Simpson, et al.
Published: (2011-02-01)

Temporal Characterization of Behavioral and Hippocampal Dysfunction in the YAC128 Mouse Model of Huntington’s Disease
by: Cristine de Paula Nascimento-Castro, et al.
Published: (2022-06-01)

Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease
by: Kun Huang, et al.
Published: (2010-10-01)

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease
by: Hua Zhang, et al.
Published: (2008-07-01)

Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease
by: Mandi E. Schmidt, et al.
Published: (2018-06-01)

Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT
by: Cesar L. Moreno, et al.
Published: (2016-01-01)

Pain in Huntington’s disease and its potential mechanisms
by: Jiajie Li, et al.
Published: (2023-07-01)

DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease
by: Mandi E. Schmidt, et al.
Published: (2020-11-01)

Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics
by: Lisa M. Stanek, et al.
Published: (2019-09-01)

Antisense oligonucleotide-mediated disruption of HTT caspase-6 cleavage site ameliorates the phenotype of YAC128 Huntington disease mice
by: Elsa C. Kuijper, et al.
Published: (2024-01-01)

A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease
by: Anna Kotowska-Zimmer, et al.
Published: (2022-06-01)

Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains
by: Francesca Persichetti, et al.
Published: (1994-12-01)

Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease
by: Kristina Bečanović, et al.
Published: (2021-10-01)

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
by: Rebecca Kusko, et al.
Published: (2018-05-01)

Testicular degeneration in Huntington disease
by: Jeremy M. Van Raamsdonk, et al.
Published: (2007-06-01)

Molecular mechanisms involved in the pathogenesis of Huntington's disease /
by: 506084 Perandones, Claudia, et al.
Published: (c201)

CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease
by: Yun-Sik Choi, et al.
Published: (2009-11-01)

Multiplatform metabolomic analysis of the R6/2 mouse model of Huntington’s disease
by: Masayo Hashimoto, et al.
Published: (2021-10-01)

Induced Pluripotent Stem Cell-Derived Neural Stem Cell Transplantations Reduced Behavioral Deficits and Ameliorated Neuropathological Changes in YAC128 Mouse Model of Huntington's Disease
by: Abeer Al-Gharaibeh, et al.
Published: (2017-11-01)

Author Correction: Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease
by: Kristina Bečanović, et al.
Published: (2021-12-01)

Suicidal behaviour in huntington disease
by: R. Mota Freitas, et al.
Published: (2021-04-01)

Effects of Exercise on Skeletal Muscle Pathophysiology in Huntington’s Disease
by: Bruno Trovato, et al.
Published: (2022-05-01)

Altered cortical processing of sensory input in Huntington disease mouse models
by: Marja D. Sepers, et al.
Published: (2022-07-01)

P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease
by: Jing Fan, et al.
Published: (2012-03-01)

Analysis of LINE1 Retrotransposons in Huntington’s Disease
by: Lavinia Floreani, et al.
Published: (2022-01-01)

Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington’s Disease
by: Cristine de Paula Nascimento-Castro, et al.
Published: (2018-01-01)

Striosome-matrix pathology and motor deficits in the YAC128 mouse model of Huntington's disease
by: Collene Lawhorn, et al.
Published: (2008-12-01)

Glycolipid and ganglioside metabolism imbalances in Huntington's disease
by: Paula A. Desplats, et al.
Published: (2007-09-01)

The contribution of preclinical magnetic resonance imaging and spectroscopy to Huntington’s disease
by: Jean-Baptiste Pérot, et al.
Published: (2024-02-01)

Microarray profiling of hypothalamic gene expression changes in Huntington’s disease mouse models
by: Elna Dickson, et al.
Published: (2022-11-01)

Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease
by: Zena DeMarch, et al.
Published: (2008-06-01)

Huntingtin-Associated Protein 1A Regulates Store-Operated Calcium Entry in Medium Spiny Neurons From Transgenic YAC128 Mice, a Model of Huntington’s Disease
by: Magdalena Czeredys, et al.
Published: (2018-10-01)

Cortical and Striatal Circuits in Huntington’s Disease
by: Sonja Blumenstock, et al.
Published: (2020-02-01)

Physiotherapy in Huntington’s disease
by: Hanne Ludt Fossmo, et al.
Published: (2013-01-01)